CARDIOME REPORTS RESULTS FROM OXYPURINOL STUDY

Cardiome Pharma has reported results from its Phase II clinical trial evaluating Oxypurinol in 405 congestive heart failure patients.

The study measured the clinical impact of 600mg daily oral dosing of Oxypurinol for 24 weeks on the clinical outcomes in New York Heart Association Class 3 and Class 4 CHF patients receiving standard CHF therapy. Oxypurinol failed to demonstrate a statistically significant benefit over placebo in the primary composite endpoint.

In addition, no benefits over placebo were observed in Minnesota CHF Quality of Life index and time to acute clinical events (mortality plus re-hospitalization for heart failure) as secondary endpoints. A significant reduction in serum uric acid levels was observed in patients receiving Oxypurinol.